Global Genomic Cancer Testing Market Strategic Research Report

Scope of the Report

The global Genomic Cancer Testing market size is predicted to grow from US$ 16,455 million in 2025 to US$ 30,739 million in 2032; it is expected to grow at a CAGR of 9.4% from 2026 to 2032.

Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.

Gross Profit Margin Levels

Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not "how much money is made per sample tested," but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.

Industry Drivers

The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an "optional item" into "part of the standard process"—the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.

This report presents a comprehensive overview of the global Genomic Cancer Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Next-Generation Sequencing (NGS) Testing Products
• Digital PCR (dPCR) Testing Products
• Others

Segment by Sample Type

• Tissue Sample Testing
• Blood Biopsy
• Others

Segment by Cancer Type Coverage

• Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
• Genome Testing Products Specifically For Single Cancer Types
• Others

Segment by Application

• Healthcare Institutions
• Biopharmaceuticals and Pharmaceuticals
• Independent Medical Laboratories
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Genomic Cancer Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Healthcare Institutions, Biopharmaceuticals and Pharmaceuticals, Independent Medical Laboratories evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact